New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
On December 20, 2021, Amgen announced the FDA approval of Otezla (apremilast), for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.
Download PDF
Return to publications
